SCHEMBL874743

SCHEMBL874743

O=C(Nc1ccc(CCS(=O)(=O)C(CCn2nnc3ccccc3c2=O)C(=O)O)cc1)c1cccc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 2/20 0.41
GPR139 Q6DWJ6 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HSD17B10 Q99714 1/20 0.40
HDAC1 Q13547 1/20 0.40
MAPK10 P53779 1/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL874644 0.92 KMT2A (0.46) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL876900 0.91 GPR139 (0.44) SMN1; SMN2KMT2AMEN1NPC1KDM4E
SCHEMBL877387 0.89 TSHR (0.49) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL875418 0.88 KMT2A (0.45) KMT2AMEN1RAB9ANPC1KDM4E
SCHEMBL874359 0.87 GPR139 (0.46) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL874844 0.87 KMT2A (0.46) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL874657 0.84 GPR139 (0.48) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL874191 0.83 ALOX15 (0.45) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL877111 0.82 ALDH1A1 (0.45) KMT2AMEN1RAB9AKDM4EALDH1A1
SCHEMBL876948 0.81 MAPK10 (0.43) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US claimed
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 SMN1; SMN2 3367/4885KMT2A 3501/4885MEN1 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.